Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.53 |
| ▸ | ACACA | Q13085 | 3/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | BAX | Q07812 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045126 | 0.85 | PTGS1 (0.67) | ACACBACACAPTGS1 | |
| SCHEMBL155984 | 0.85 | ALDH1A1 (0.54) | SMN1; SMN2PPARAKEAP1NFE2L2 | |
| SCHEMBL103235 | 0.85 | ALDH1A1 (0.54) | SMN1; SMN2PPARAKEAP1NFE2L2 | |
| SCHEMBL104518 | 0.85 | ALDH1A1 (0.54) | SMN1; SMN2PPARAKEAP1NFE2L2 | |
| SCHEMBL11568688 | 0.84 | PPARG (0.54) | ACACBACACASRD5A2PTGS1LTA4H | |
| SCHEMBL17295989 | 0.83 | LDHA (0.52) | PTGS1 | |
| SCHEMBL17295985 | 0.83 | LDHA (0.52) | PTGS1 | |
| SCHEMBL3829660 | 0.83 | LDHA (0.52) | PTGS1 | |
| Ammonia Solution, Strong SCHEMBL38660904 | 0.83 | ALDH1A1 (0.53) | SMN1; SMN2PPARAKEAP1NFE2L2 | |
| Methane SCHEMBL9122539 | 0.83 | ALDH1A1 (0.53) | SMN1; SMN2PPARAKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | ACACB 4740/4885ACACA 2439/4885SRD5A2 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.